FDA Gives Priority Review to Lynparza as First-line Maintenance Therapy for Advanced Ovarian Cancer

FDA Gives Priority Review to Lynparza as First-line Maintenance Therapy for Advanced Ovarian Cancer
The U.S. Food and Drug Administration (FDA) has agreed to review the use of Lynparza (olaparib) tablets as a maintenance treatment for women newly diagnosed with advanced ovarian cancer, Merck announced in a press release. The application, which is for women with BRCA mutations in complete or partial response after standard first-line platinum-based chemotherapy, received priority review status. A decision is

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *